Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?

Overview

Journal Horm Cancer

Date 2019 Jan 19

PMID 30656558

Citations 7

Authors

Rosalia I Cordo Russo

Maria F Chervo

Santiago Madera

Eduardo H Charreau

Patricia V Elizalde

Affiliations

Soon will be listed here.

Abstract

Membrane overexpression of ErbB-2 (MErbB-2), a member of the ErbB family of receptor tyrosine kinases, occurs in 15-20% of breast cancers (BC) and constitutes a therapeutic target in this BC subtype (ErbB-2-positive). Although MErbB-2-targeted therapies have significantly improved patients' clinical outcome, resistance to available drugs is still a major issue in the clinic. Lack of accurate biomarkers for predicting responses to anti-ErbB-2 drugs at the time of diagnosis is also an important unresolved issue. Hence, a better understanding of the ErbB-2 signaling pathway constitutes a critical task in the battle against BC. In its canonical mechanism of action, MErbB-2 activates downstream signaling pathways, which transduce its proliferative effects in BC. The dogma of ErbB-2 mechanism of action has been challenged by the demonstration that MErbB-2 migrates to the nucleus, where it acts as a transcriptional regulator. Accumulating findings demonstrate that nuclear ErbB-2 (NErbB-2) is involved in BC growth and metastasis. Emerging evidence also reveal a role of NErbB-2 in the response to available anti-MErbB-2 agents. Here, we will review NErbB-2 function in BC and will particularly discuss the role of NErbB-2 as a novel target for therapy in ErbB-2-positive BC.

Citing Articles

Comparative efficacy and safety of targeted therapy and immunotherapy for HER2-positive breast cancer: a systematic review and network meta-analyses.

Gu S, Liu Y, Huang Y, Lin W, Li K Front Oncol. 2024; 14:1331055.

PMID: 38634057 PMC: 11021689. DOI: 10.3389/fonc.2024.1331055.

ErbB2/HER2 receptor tyrosine kinase regulates human papillomavirus promoter activity.

Mikulicic S, Shamun M, Massenberg A, Franke A, Freitag K, Doring T Front Immunol. 2024; 15:1335302.

PMID: 38370412 PMC: 10869470. DOI: 10.3389/fimmu.2024.1335302.

Long non-coding RNAs affecting cell metabolism in cancer.

Agostini M, Mancini M, Candi E Biol Direct. 2022; 17(1):26.

PMID: 36182907 PMC: 9526990. DOI: 10.1186/s13062-022-00341-x.

Plasmid DNA for Therapeutic Applications in Cancer.

Martinez-Puente D, Perez-Trujillo J, Zavala-Flores L, Garcia-Garcia A, Villanueva-Olivo A, Rodriguez-Rocha H Pharmaceutics. 2022; 14(9).

PMID: 36145609 PMC: 9503848. DOI: 10.3390/pharmaceutics14091861.

TAp63 regulates bone remodeling by modulating the expression of TNFRSF11B/Osteoprotegerin.

Lena A, Foffi E, Agostini M, Mancini M, Annicchiarico-Petruzzelli M, Aberdam D Cell Cycle. 2021; 20(22):2428-2441.

PMID: 34763601 PMC: 8794505. DOI: 10.1080/15384101.2021.1985772.

References

Tan M, Jing T, Lan K, Neal C, Li P, Lee S . Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell. 2002; 9(5):993-1004. DOI: 10.1016/s1097-2765(02)00510-5. View

Bose R, Kavuri S, Searleman A, Shen W, Shen D, Koboldt D . Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2012; 3(2):224-37. PMC: 3570596. DOI: 10.1158/2159-8290.CD-12-0349. View

Wang Y, Yamaguchi H, Huo L, Du Y, Lee H, Lee H . The translocon Sec61beta localized in the inner nuclear membrane transports membrane-embedded EGF receptor to the nucleus. J Biol Chem. 2010; 285(49):38720-9. PMC: 2992305. DOI: 10.1074/jbc.M110.158659. View

Venturutti L, Romero L, Urtreger A, Chervo M, Russo R, Mercogliano M . Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis. Oncogene. 2015; 35(17):2208-22. DOI: 10.1038/onc.2015.281. View

Salatino M, Schillaci R, Proietti C, Carnevale R, Frahm I, Molinolo A . Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone.... Oncogene. 2004; 23(30):5161-74. DOI: 10.1038/sj.onc.1207659. View

Huang T, Wu F, Loeb G, Hsu R, Heidersbach A, Brincat A . Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem. 2009; 284(27):18515-24. PMC: 2709372. DOI: 10.1074/jbc.M109.006676. View

Esteva F, Valero V, Booser D, Guerra L, Murray J, Pusztai L . Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(7):1800-8. DOI: 10.1200/JCO.2002.07.058. View

Proietti C, Salatino M, Rosemblit C, Carnevale R, Pecci A, Kornblihtt A . Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol Cell Biol. 2005; 25(12):4826-40. PMC: 1140598. DOI: 10.1128/MCB.25.12.4826-4840.2005. View

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View

10.

Nagata Y, Lan K, Zhou X, Tan M, Esteva F, Sahin A . PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6(2):117-27. DOI: 10.1016/j.ccr.2004.06.022. View

11.

Wang S, Hung M . Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res. 2009; 15(21):6484-9. PMC: 5537741. DOI: 10.1158/1078-0432.CCR-08-2813. View

12.

Romond E, Perez E, Bryant J, Suman V, Geyer Jr C, Davidson N . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1673-84. DOI: 10.1056/NEJMoa052122. View

13.

Ranger J, Levy D, Shahalizadeh S, Hallett M, Muller W . Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer Res. 2009; 69(17):6823-30. PMC: 2841985. DOI: 10.1158/0008-5472.CAN-09-1684. View

14.

Wang S, Lien H, Xia W, Chen I, Lo H, Wang Z . Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell. 2004; 6(3):251-61. DOI: 10.1016/j.ccr.2004.07.012. View

15.

Xia W, Liu Z, Zong R, Liu L, Zhao S, Bacus S . Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. Mol Cancer Ther. 2011; 10(8):1367-74. PMC: 3836594. DOI: 10.1158/1535-7163.MCT-10-0991. View

16.

Olayioye M, Neve R, Lane H, Hynes N . The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19(13):3159-67. PMC: 313958. DOI: 10.1093/emboj/19.13.3159. View

17.

Diaz Flaque M, Galigniana N, Beguelin W, Vicario R, Proietti C, Russo R . Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Breast Cancer Res. 2013; 15(6):R118. PMC: 3978912. DOI: 10.1186/bcr3587. View

18.

Scaltriti M, Verma C, Guzman M, Jimenez J, Parra J, Pedersen K . Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2008; 28(6):803-14. DOI: 10.1038/onc.2008.432. View

19.

Singh J, Jhaveri K, Esteva F . HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer. 2014; 111(10):1888-98. PMC: 4229628. DOI: 10.1038/bjc.2014.388. View

20.

Marfori M, Mynott A, Ellis J, Mehdi A, Saunders N, Curmi P . Molecular basis for specificity of nuclear import and prediction of nuclear localization. Biochim Biophys Acta. 2010; 1813(9):1562-77. DOI: 10.1016/j.bbamcr.2010.10.013. View